Dyax Corp. (NASDAQ:DYAX)’s Principal Focus On Commercial Therapies


Dallas, Texas 02/12/2014 (FINANCIALSTRENDS) – Dyax Corp. (NASDAQ:DYAX) is the Burlington, MA based biopharmaceutical company which brings two businesses. The first is the Franchise system called as the Angioedema Phage Display Licensing and the second is the Funded Research Program. The company works on developing as well as identifying treatments for patients who struggle with ailments such as plasma kallikrein or bradykinin, also known as mediated angioedema.

Principal focus                                                                                      

Dyax Corp.(NASDAQ:DYAX) is focused on the development of commercial therapies which will bring relief and care for patients who are suffering from different types of angioedema. This includes such types such as the hereditary angioedema or HAE. Sometimes there are conditions which are caused due ACE-inhibitor which results in the angioedema of another kind, called as ACEI-AE.  Another type is the angioedema caused by unknown origin. This is also called as idiopathic angioedema.

Dyax Corp.(NASDAQ:DYAX) has since developed the product called as Kalbitor or ecallantide. However, this can be used in the US only and is approved for treatment of acute instances of HAE. For treating patients who are not in the US, the company has also chosen to commercialize its KALBITOR in some of the markets. However, the use of this drug is yet to be evaluated in some of the markets.

Dyax Corp.(NASDAQ:DYAX) is also known to use its extensive phage display technology along with the Licensing and Funded Research Program to further improve the services and products it offers for treating this condition.

Financial Overview

Dyax Corp.(NASDAQ:DYAX) currently trades on the stock market at $8.67. This price is higher by 3.34%, indicate a steady upward trend for this pharmaceutical company. As of Feb 11,2014, the company reported infra-day high of $8.93 and low of $8.38. The 52 week low for the company stands at $2.26 and the infra-day high is $9.72. The average volume for the stock was 1.03 million. The market cap for the company is reported to be $947.29million. Besides, the EPS is -0.30. Beta is 1.67.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.